EASTAMPTON, N.J., Dec. 15, 2014 (GLOBE NEWSWIRE) -- Epicore BioNetworks Inc. (TSX-V:EBN) is pleased to announce the appointment of a new Research Manager, Dr. Russell J. Jerusik. The appointment reflects Epicore's commitment to developing new environmental biotechnology products to solve problems in aquaculture and other industries. Dr. Jerusik will be responsible for all laboratory and field R&D projects and will oversee technical service, product quality and process development activities.
Dr. Jerusik earned microbiology degrees from Upsala College and the University of Georgia. He has over twenty years of laboratory and business management experience. He has developed patent-pending test methods for rapid detection of bacterial spores. He has conducted technical service for wastewater microbiology and spent many years technically supporting micro-biocide businesses. His field development experience spans several continents.
With this important addition to our technical staff Epicore expects to accelerate its product development program. The program is targeted to deliver environmentally friendly solutions to world problems in aquaculture, agriculture and other industries.
Russell will be based at Epicore's Eastampton, NJ headquarters. He can be reached by email at Russell.Jerusik@EpicoreBioNetworks.com.
Epicore BioNetworks Inc. is a leading producer of environmental biotechnology and animal nutrition products. It manufactures in the USA and markets worldwide to a variety of industries to reduce environmental pollution and increase operational productivity.
Epicore BioNetworks Inc. is a public corporation with a registered office in Calgary, Alberta, Canada and with shares listed on the TSX Venture Exchange (symbol EBN). [Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.]
This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the company might differ materially from the results, performance or achievements of the company expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, those regarding development of new products to support future growth of the Company. We can provide no assurance that the company will be able to generate sufficient cash to meet its obligations. We are subject to various risks, including the uncertainties of product development, markets for our products and regulatory review, our need for additional capital to fund our operations, our reliance on collaborative partners, our history of losses, and other risks inherent in the biotechnology industry.